| Literature DB >> 35898797 |
Muhammed Shahriar Zaman1, Setareh Ghahari2, Mary Ann McColl2.
Abstract
Background: Communication breakdown between patients and health care professionals poses an accessibility gap preventing adequate health care. The Empowered Patient Program was developed to support people with Parkinson's in improving their health communication skills/strategies and thus facilitate the accessibility gap in their care. Objective: Our pilot study aimed to test the feasibility and preliminary effect of the Empowered Patient Program within a small cohort of individuals with Parkinson's disease.Entities:
Keywords: Health communication; Parkinson’s disease; Program development
Year: 2022 PMID: 35898797 PMCID: PMC9310115 DOI: 10.1016/j.prdoa.2022.100156
Source DB: PubMed Journal: Clin Park Relat Disord ISSN: 2590-1125
Socio-demographic and clinical characteristics of the program participants (n = 8) in pre-test-post-test study.
| Variables | Frequency† | |
|---|---|---|
| Age | ||
| Median | 72 years | |
| Min-Max | 55–82 years | |
| Sex | ||
| Male | 3 (37.5 %) | |
| Female | 5 (62.5 %) | |
| Educational level | ||
| High School Diploma | 3 (37.5 %) | |
| Bachelor’s Degree | 3 (37.5 %) | |
| Post-graduate degree | 2 (25.5 %) | |
| Occupation | ||
| Retired | 7 (87.5 %) | |
| Self-employed | 1 (12.5 %) | |
| Time since start of symptoms | ||
| Median | 2.25 years | |
| Min-Max | 1.5–24 years | |
| Health Utility Index (score range 0 to 1) | ||
| Median | 0.79 | |
| Min-Max | 0.18–1.00 | |
| Number of co-morbidities | ||
| None | 2 (25.0 %) | |
| 1–2 | 4 (50.0 %) | |
| 3–4 | 1 (12.5 %) | |
| 5–6 | 1 (12.5 %) | |
| † Results are shown in frequency and percent, if not mentioned otherwise. | ||
Preliminary effect of the Empowered Patient program in the pre-test-post-test study (n = 8).
| Measure | Time point | Mean | St. Deviation | Median | Range | P-value |
|---|---|---|---|---|---|---|
| Pre-test | 3.84 | 0.62 | 3.83 | 2.87–4.74 | ||
| Post-test | 4.50 | 0.27 | 4.46 | 4.13–5.00 | 0.017 | |
| Pre-test | 4.13 | 0.50 | 4.17 | 3.38–4.66 | ||
| Post-test | 4.27 | 0.41 | 4.50 | 3.50–4.69 | 0.309 | |
| Follow-up | 4.23 | 0.24 | 4.34 | 3.81–4.44 | 0.674 | |
| Pre-test | 3.04 | 1.08 | 3.00 | 1.67–4.67 | ||
| Post-test | 3.58 | 1.05 | 3.67 | 2.33–4.67 | 0.041⁑ | |
| Follow-up | 3.46 | 0.92 | 3.67 | 1.67–4.67 | 0.348 | |
| Pre-test‖ | 3.11 | 0.64 | 3.04 | 2.00–4.00 | ||
| Post-test | 3.15 | 0.32 | 3.10 | 2.60–3.60 | 0.833⁑ | |
| Follow-up | 3.38 | 0.23 | 3.40 | 3.00–3.60 | 0.357 |
Level of significant was tested by Wilcoxon Signed Ranks Test; ⁑ The p-value is tested from pre-test to post-test; The p-value is tested from pre-test to follow-up.